Boston Scientific Corporation
BSX · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $144,658 | $158,806 | $149,020 | $131,676 |
| - Cash | $0 | $534 | $725 | $414 |
| + Debt | $0 | $12,027 | $11,708 | $11,147 |
| Enterprise Value | $144,658 | $170,299 | $160,003 | $142,409 |
| Revenue | $5,065 | $5,061 | $4,663 | $4,561 |
| % Growth | 0.1% | 8.5% | 2.2% | – |
| Gross Profit | $3,542 | $3,424 | $2,950 | $2,671 |
| % Margin | 69.9% | 67.7% | 63.3% | 58.6% |
| EBITDA | $1,026 | $1,367 | $1,217 | $1,071 |
| % Margin | 20.3% | 27% | 26.1% | 23.5% |
| Net Income | $755 | $793 | $674 | $566 |
| % Margin | 14.9% | 15.7% | 14.5% | 12.4% |
| EPS Diluted | 0.5 | 0.53 | 0.451 | 0.38 |
| % Growth | -5.7% | 17.4% | 18.9% | – |
| Operating Cash Flow | – | $1,286 | $541 | $1,456 |
| Capital Expenditures | – | -$190 | -$187 | -$293 |
| Free Cash Flow | – | $1,096 | $354 | $1,163 |